select a format

Single User License
USD 3500 INR 224315
Site License
USD 7000 INR 448630
Corporate User License
USD 10500 INR 672945

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Lysine-Specific Histone Demethylase 1A Lysine K-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.-Pipeline Review, H1 2016

Lysine-Specific Histone Demethylase 1A Lysine K-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.-Pipeline Review, H1 2016


  • Products Id :- GMDHC0100TDB
  • |
  • Pages: 63
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Pipeline Review, H1 2016', provides in depth analysis on Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted pipeline therapeutics.

The report provides comprehensive information on the Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)

The report reviews Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted therapeutics and enlists all their major and minor projects

The report assesses Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) Overview 7

Therapeutics Development 8

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Products under Development by Stage of Development 8

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Products under Development by Therapy Area 9

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Products under Development by Indication 10

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Products under Development by Companies 14

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Products under Development by Universities/Institutes 17

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Companies Involved in Therapeutics Development 24

4SC AG 24

Beactica AB 25

F. Hoffmann-La Roche Ltd. 26

GlaxoSmithKline Plc 27

Incyte Corporation 28

Oryzon Genomics S.A. 29

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Drug Profiles 30

4SC-202-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Drugs to Target LSD-1 for Undisclosed Indications-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

GSK-2879552-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

INCB-59872-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ORY-2001-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

RG-6016-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

RN-1-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecule to Inhibit LSD1 for Oncology-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecules to Inhibit LSD-1 for Oncology-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules to Inhibit LSD1 and LSD2 for Oncology-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Inhibit LSD1 for Alzheimer's Disease, Oncology and Viral Infections-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

SP-2509-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

SP-2528-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

SP-2577-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Synthetic Peptide to Inhibit LSD-1 for Oncology-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Dormant Projects 50

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.)-Featured News & Press Releases 53

Apr 11, 2016: Data on ORY-1001 to Be Presented at the AACR Annual Meeting 2016 in New Orleans 53

Apr 04, 2016: ORYZON Announces First Subject Dosed in Phase I Healthy Volunteer Study Evaluating Oral Epigenetic drug ORY-2001 for Alzheimer's Disease 53

Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 54

Jan 29, 2016: Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer's Disease 54

Dec 29, 2015: Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors 55

Dec 16, 2015: ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer's Disease 56

Dec 07, 2015: Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology 56

Nov 10, 2015: Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001 57

Nov 02, 2015: Oryzon Announces Oral Presentation on ORY-2001 at 8th Annual Clinical Trials on Alzheimer's Disease Conference 57

Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 58

Sep 08, 2015: ORYZON Achieves Milestone in the Clinical Development of ORY-1001 59

Aug 24, 2015: ORYZON to Present at the 15 Annual Biotech in Europe Forum for Global Partnering & Investment in Basel, Switzerland 59

Aug 18, 2015: First notice of allowance received from the European Patent Office for one of its LSD1 composition-of-matter EP patent applications 60

Aug 13, 2015: 4SC Strengthens Patent Protection For Its Epigenetic Cancer Drug Candidate 4SC-202 In Growth Market China 61

Jul 20, 2015: ORYZON Genomics to present at the 2015 Alzheimer's Association International Conference 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Figures

Number of Products under Development for, H1 2016 8

Number of Products under Development by Therapy Area, H1 2016 9

Number of Products under Development by Top 10 Indication, H1 2016 10

Comparative Analysis by Early Stage Products, H1 2016 13

Assessment by Monotherapy/Combination Products, H1 2016 19

Number of Products by Stage and Mechanism of Actions, H1 2016 20

Number of Products by Stage and Routes of Administration, H1 2016 21

Number of Products by Molecule Types, H1 2016 22

Number of Products by Stage and Molecule Type, H1 2016 22

List of Tables

Number of Products under Development for, H1 2016 8

Number of Products under Development by Therapy Area, H1 2016 9

Number of Products under Development by Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 13

Number of Products under Development by Companies, H1 2016 14

Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Products under Investigation by Universities/Institutes, H1 2016 18

Assessment by Monotherapy/Combination Products, H1 2016 19

Number of Products by Stage and Mechanism of Action, H1 2016 20

Number of Products by Stage and Route of Administration, H1 2016 21

Number of Products by Stage and Molecule Type, H1 2016 23

Pipeline by 4SC AG, H1 2016 24

Pipeline by Beactica AB, H1 2016 25

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 26

Pipeline by GlaxoSmithKline Plc, H1 2016 27

Pipeline by Incyte Corporation, H1 2016 28

Pipeline by Oryzon Genomics S.A., H1 2016 29

Dormant Projects, H1 2016 50

Dormant Projects (Contd..1), H1 2016 51

Dormant Projects (Contd..2), H1 2016 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

Beactica AB

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Incyte Corporation

Oryzon Genomics S.A.

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) Therapeutic Products under Development, Key Players in Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) Therapeutics, Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) Pipeline Overview, Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) Pipeline, Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com